Insulin Delivery Devices Market with Business Strategy, Key Drivers, Opportunities, Top Key Companies Analysis and Forecast

Browse 151 market data Tables and 59 Figures spread through 229 Pages and in-depth TOC on "Insulin Delivery Devices Market by Type (Insulin Pens [Reusable, Disposable], Insulin Pumps (Tethered, Tubeless), Insulin Syringes, Insulin Pen Needles (Standard, Safety)), End User (Hospitals & Clinics, Patients/Homecare) - Global Forecast to 2028
Insulin Delivery Devices Market [https://www.marketsandmarkets.com/Market-Reports/insulin-delivery-device-market-107632092.html?utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr] in terms of revenue was estimated to be worth $30.8 Billion in 2023 and is poised to reach $46.2 Billion by 2028, growing at a CAGR of 8.5% from 2023 to 2028 according to a new report by MarketsandMarkets Trademark . As diabetes prevalence has increased, there is an increasing demand for more efficient diabetes care solutions. Furthermore, government support and favourable reimbursement schemes as well as technological advanced insulin delivery devices are main factors driving market growth.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=107632092 [https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=107632092&utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr]

"Insulin pen delivery device segment to grow at the highest CAGR during the forecast period."

Segments of the devices taken into consideration in the insulin delivery device market include insulin pens, insulin pumps, insulin syringes, and pen needles. The insulin subsegment includes reusable pens and disposable pens. The market for reusable insulin pens is anticipated to continue to grow at the highest CAGR during the forecast period. This is primarily because patients can use the same pen multiple times by replacing the insulin cartridge are more economical compared to disposable insulin pens.

"The patients/homecare segment to grow at the highest CAGR during the forecast period"

The end users in the insulin delivery device market are hospitals&clinics and patients/homecare. The patients/homecare segment is anticipated to grow at the highest CAGR during the forecast period. Presence of a favorable reimbursement scenario, increasing preference for less invasive technologies to administer insulin, and user friendliness have contributed for the growth of this segment.

"North America accounted for the largest share of the Insulin delivery device market, followed by Europe in 2022"

North America, followed by Europe, held the largest market share in 2022. The market for insulin delivery device in North America was further dominated by the US. This is driven on by a number of factors, such as the rising prevalence of diabetes, technological advancements in insulin delivery devices, reimbursement support, and increasing emphasis on raising the quality of patient care.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=107632092 [https://www.marketsandmarkets.com/requestsampleNew.asp?id=107632092&utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr]

Insulin Delivery Devices Market Dynamics:

Drivers:

* Growing prevalence of diabetic population

Restraints:

* High cost and lack of reimbursement in developing countries

Opportunities:

* Increasing healthcare expenditure on diabetes care

Challenges:

* Needlestick injuries and misuse of injection pens

Key Market Players:

The prominent players operating in the global insulin delivery devices market are Embecta Corp. (Formely Becton, Dickinson and Company Diabetes Care Business (US), Ypsomed Holding AG (Switzerland), Tandem Diabetes Care (US), Insulet Corporation (US), Biocon Limited (India), Novo Nordisk A/S (Denmark), Medtronic (Ireland), Sanofi (France), Eli Lilly and Company (US), Roche Diabetes Care (Switzerland), Owen Mumford (England), Mrdtrum Technologies Inc. (China), Terumo Corporation (Japan), Wockhardt (India), Cerur Corporation (Switzerland), EoFlow CO., Ltd. (South Korea), Hindustan Syringes & Medical Devices Ltd (India), Sooil Developments CO., Ltd (Korea), Sungshim Medical Co., Ltd. (South Korea), Vicentra B.V. (Netherland), Debiotech SA (Switzerland), Jiangsu Delfu Medical Device Co., Ltd (China), Haselmeier (Germany), Mannkind Corporation (US), HTL-Sterfa S.A. (Poland).

Recent Developments:

* In 2023, Embecta Corp. opened a new global headquarters office at 300 Kimball Drive, Suite 300, IN Parsippany, N.J. The site is expected to be home to members of the leadership team, global support functions and North American commercial organization to develop and provide solutions that make life better for people coping with diabetes.
* In 2023, Eli Lilly announced price reductions of 70% for its most prescribed insulins and an expansion of its Insulin Value Program that caps patients out-of-pocket cost at USD 35 or less per month.
* In 2023, Novo Nordisk launched the first smart insulin pens NovoPen 6 and NovoPen Echo Plus available in the UK.
* In 2022, Medtronic entered into a set of definitive agreements to acquire EOFlow Co. Ltd., a manufacturer of the EOPatch device- a tubeless, wearable and fully disposable insulin delivery device.

Get 10% Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=107632092 [https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=107632092&utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr]

Insulin Delivery Devices Market Advantages:

* Enhanced Convenience: Insulin delivery devices provide a convenient and user-friendly way for patients to administer insulin. Whether it's insulin pens, pumps, or patches, these devices simplify the process of insulin delivery, reducing the reliance on traditional syringes and vials.
* Improved Glycemic Control: The advanced features of insulin delivery devices, such as smart pumps with continuous glucose monitoring (CGM) integration, allow for more precise and personalized insulin dosing. This results in better glycemic control, reducing the risk of hyperglycemia and hypoglycemia episodes, and ultimately lowering the risk of diabetes-related complications.
* Increased Treatment Compliance: Insulin delivery devices offer greater ease of use and convenience, leading to improved treatment compliance among patients. The reduction in the number of injections or the need for frequent adjustments in insulin dosing can positively impact patient adherence to their prescribed treatment plan.
* Precision and Accuracy: Insulin delivery devices are designed to deliver insulin with greater precision and accuracy, ensuring consistent dosing. This reduces the potential for dosing errors and ensures patients receive the correct amount of insulin they need.
* Flexibility in Lifestyle: Insulin pumps and patch-based systems offer more flexibility for patients in managing their diabetes. With programmable basal rates and bolus doses, patients can adjust their insulin delivery to match their lifestyle, exercise, and dietary habits.
* Reduced Pain and Discomfort: Insulin delivery devices often use finer needles or even needleless systems, which can lead to reduced pain and discomfort during insulin administration compared to traditional syringes.
* Continuous Glucose Monitoring (CGM) Integration: Many modern insulin pumps come with CGM integration, allowing real-time monitoring of glucose levels. This feature helps patients proactively adjust insulin dosing and provides insights into glucose trends, enabling more proactive diabetes management.
* Potential for Closed-Loop Systems: The insulin delivery device market is rapidly progressing toward closed-loop or artificial pancreas systems, where insulin delivery is fully automated based on continuous glucose monitoring data. This technology has the potential to revolutionize diabetes management by minimizing the need for constant manual intervention.
* Improved Data Tracking and Analysis: Insulin delivery devices often come with software or mobile apps that enable patients to track and analyze their blood glucose levels, insulin dosing, and other relevant data. This facilitates better self-management and empowers patients to make informed decisions about their diabetes care.
* Advancements in Telemedicine: The integration of insulin delivery devices with telemedicine platforms allows healthcare providers to remotely monitor patients' glucose levels, adjust insulin therapy, and provide timely feedback, fostering a more personalized and accessible approach to diabetes management.

In summary, the insulin delivery devices market offers a wide array of advantages, including improved convenience, enhanced glycemic control, increased treatment compliance, precision, flexibility, and a reduced burden of pain and discomfort. As technology continues to advance, these benefits are expected to further improve the lives of individuals living with diabetes.

Media Contact
Company Name: MarketsandMarkets Trademark Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=insulin-delivery-devices-market-with-business-strategy-key-drivers-opportunities-top-key-companies-analysis-and-forecast]
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/insulin-delivery-device-market-107632092.html



This release was published on openPR.